Authors
Latest:
Dr. Banerji on the Clinical Activity of VS-6766/Defactinib in KRAS-Mutant TumorsUdai Banerji, MD, discusses the results from a phase 1 trial with the combination of VS-6766 (CH5126766) and defactinib in KRAS-mutant tumors.
Latest:
Key Takeaways: Advancements and Challenges in Kidney Cancer TreatmentLeading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.
Latest:
Dr. Lassen Discusses TRK Fusions in Pediatric PatientsUlrik Lassen, MD, PhD, head of the Phase I Unit at Rigshospitalet, discusses TRK fusions in pediatric patients with cancer.
Latest:
Dr. Umamaheswar Duvvuri on Impact of Multiple Genetic Mutations in Advanced Thyroid CancerUmamaheswar Duvvuri, MD, PhD, Assistant Professor of Otolaryngology (ENT) at the University of Pittsburgh Medical Center, talks about potential genetic signatures for locally advanced, well differentiated thyroid cancers.
Latest:
Dr. Capitanio Discusses Adjuvant Therapy for High-Risk Kidney CancerUmberto Capitanio, MD, FEBU, department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.
Latest:
Unanswered Questions With the Role of TMB in NSCLCUmberto Malapelle, PhD, assistant professor, University of Naples Federico II, discusses unanswered questions regarding the role of tumor mutational burden in non–small cell lung cancer.
Latest:
Dr. Mahantshetty on Challenges With Concomitant Chemoradiation Trial in Cervical CancerUmesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses challenges with a trial (NCT00193791) conducted by Tata Memorial Hospital seeking to solidify the impact of concomitant chemoradiation with FIGO stage IIIb squamous cervical cancer.
Latest:
Future Outlook for Treatment of Endometrial CancerThe panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.
Latest:
Mom-Doctor Versus Doctor-MomI am still juggling tasks as I try to balance my life at home and life at work.
Latest:
US Oncology Research Announces Schedule of Presentations at the 2019 American Society of Hematology Annual Meeting and ExpositionTop researchers will present abstracts on latest clinical research advancing cancer treatment options.
Latest:
In My Humble Opinion: Advice From a Second-Year FellowAfter having devoted the last decade to countless hours in medical school and internal medicine training, you have arrived on the final path of your ultimate career destination.
Latest:
Dr. Sahai on Sequencing Strategies in Metastatic Pancreatic CancerVaibhav Sahai, MBBS, assistant professor of medicine at the University of Michigan, discusses sequencing strategies in metastatic pancreatic cancer.
Latest:
Novel T-Cell Engineering Strategy Aims to Reduce GVHD in Lymphoma TransplantationsThis pilot trial is the first of its type to investigate T cell receptor alpha/beta-depleted and CD19-depleted haploidentical stem cell grafts in relapsed/refractory lymphoma patients.
Latest:
Dr. Goede on Obinutuzumab Versus Rituximab in CLLValentin Goede, MD, from the University Hospital Cologne, discusses the efficacy findings from the stage 2 CLL11 study that examined obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia with comorbidities.
Latest:
Dr Velcheti on the FDA Approval of Repotrectinib in ROS1+ Metastatic NSCLCVamsidhar Velcheti, MD, discusses the significance of the FDA approval of the ROS1 TKI repotrectinib in patients with ROS1-positive metastatic non–small cell lung cancer.
Latest:
Dr. Velcheti on the Importance of Real-World Data in NSCLCVamsidhar Velcheti, MD, discusses the importance of real-world data for patients with non–small cell lung cancer.
